Skip to main content
Equibles

Brian Ritchie

Analyst

LifeSci Advisors

Head of Investor Relations

Relmada Therapeutics, Inc. (RLMD)

Head of Investor Relations

Kamada Ltd (KMDA)

Equibles does not estimate personal net worth.

About Brian Ritchie

Brian Ritchie is recorded as Analyst at LifeSci Advisors, Head of Investor Relations at Relmada Therapeutics, Inc. (RLMD) and Head of Investor Relations at Kamada Ltd (KMDA). Brian Ritchie has spoken on 23 earnings calls across 5 companies, most recently for Relmada Therapeutics, Inc. on May 12, 2026. Those appearances were for PolyPid Ltd. (PYPD), Kamada Ltd (KMDA), Relmada Therapeutics, Inc. (RLMD), Brainsway Ltd. (BWAY) and Soleno Therapeutics Inc. Kamada Ltd is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Relmada Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Brian Ritchie spoke on are classified in the Healthcare sector. Other leadership on record at Relmada Therapeutics, Inc. includes Sergio Traversa (CEO and Board Member), Charles J. Casamento (Chairman and Board Member), Maged Shenouda (CFO) and 4 others.

Brian Ritchie on recent calls

“This afternoon, RealMata issued a press release providing a business update and outlining its financial results for the three months ended March 31, 2026. Please note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act.”
Head of Investor Relations, Relmada Therapeutics, Inc. Q1 FY2026 Earnings Call ·
“This afternoon, Ramada issued a press release providing a business update and outlining its financial results for the three months and year-ended December 31st, 2025.”
Head of Investor Relations, Relmada Therapeutics, Inc. Q4 FY2025 Earnings Call ·
“This afternoon, Relmada Therapeutics, Inc. issued a press release providing a business update and outlining its financial results for the three months ended September 30, 2025.”
Analyst — LifeSci Advisors, Relmada Therapeutics, Inc. Q3 FY2025 Earnings Call ·
“With us today are BrainsWay's Chief Executive Officer, Hadar Levy; and Chief Financial Officer, Ido Marom. The format for today's call will be a discussion of recent trends and business updates from Hadar and Ido, followed by a detailed discussion of the financials.”
Analyst — LifeSci Advisors, Brainsway Ltd. Q3 FY2025 Earnings Call ·
“Joining me from Kamada are Amir London, Chief Executive Officer, and Chaime Orlev, Chief Financial Officer. Earlier today, Kamada announced its financial results for the three months and nine months ended September 30, 2025.”
Analyst — LifeSci Advisors, Kamada Ltd Q3 FY2025 Earnings Call ·

Affiliation history

Company network

Soleno Therapeutics Inc

Biotechnology · Healthcare

1 appearance Latest appearance 2025-07-10

Leadership on record at Relmada Therapeutics, Inc.

Recent activity

Show 11 earlier activities